mTOR: Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process

The mammalian target of rapamycin (mTOR) is a pivotal regulator, integrating diverse environmental signals to control fundamental cellular functions, such as protein synthesis, cell growth, survival, and apoptosis. Embedded in a complex network of signaling pathways, mTOR dysregulation is implicated in the onset and progression of a range of human diseases, including metabolic disorders such as diabetes and cardiovascular diseases, as well as various cancers. mTOR also has a notable role in aging. Given its extensive biological impact, mTOR signaling is a prime therapeutic target for addressing these complex conditions. The development of mTOR inhibitors has proven advantageous in numerous research domains. This review delves into the significance of mTOR signaling, highlighting the critical components of this intricate network that contribute to disease. Additionally, it addresses the latest findings on mTOR inhibitors and their clinical implications. The review also emphasizes the importance of developing more effective next-generation mTOR inhibitors with dual functions to efficiently target the mTOR pathways. A comprehensive understanding of mTOR signaling will enable the development of effective therapeutic strategies for managing diseases associated with mTOR dysregulation.

[1]  Rui-yuan Jiang,et al.  PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. , 2024, Breast cancer.

[2]  A. Salminen The role of the immunosuppressive PD-1/PD-L1 checkpoint pathway in the aging process and age-related diseases , 2024, Journal of molecular medicine.

[3]  A. Vincent-Salomon,et al.  The prognosis of patients treated with everolimus for advanced ER‐positive, HER2‐negative breast cancer is driven by molecular features , 2024, The journal of pathology. Clinical research.

[4]  Yilin Ren,et al.  A Free Amino Acid Diet Alleviates Colorectal Tumorigenesis through Modulating Gut Microbiota and Metabolites , 2024, Nutrients.

[5]  P. Nghiemphu,et al.  Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma , 2024, Journal of neuro-oncology.

[6]  Shuchi Gulati,et al.  Belzutifan versus Everolimus in Advanced Kidney Cancer: A Commentary on LITESPARK-005 Trial from ESMO 2023 , 2024, Kidney cancer.

[7]  A. Naing,et al.  Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors , 2024, Cancer medicine.

[8]  F. Janku,et al.  Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies , 2023, Cancer research communications.

[9]  A. Ibrahimi,et al.  Virtual docking screening and quantitative structure-activity relationship studies to explore AKT and PI3K inhibitors acting on mTOR in cancers by theoretical biology and medical modeling , 2023, Contemporary oncology.

[10]  Ke Zhou,et al.  RapaLink-1 outperforms rapamycin in alleviating allogeneic graft rejection by inhibiting the mTORC1-4E-BP1 pathway in mice. , 2023, International immunopharmacology.

[11]  R. Costa,et al.  MTOR gene variants are associated with severe COVID-19 outcomes: A multicenter study. , 2023, International immunopharmacology.

[12]  R. Tonk,et al.  Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease , 2023, Signal transduction and targeted therapy.

[13]  B. García-Pérez,et al.  Autophagy as a Target for Non-Immune Intrinsic Functions of Programmed Cell Death-Ligand 1 in Cancer , 2023, International journal of molecular sciences.

[14]  Sulaiman K. Marafie,et al.  An Overview of the Role of Furin in Type 2 Diabetes , 2023, Cells.

[15]  Jun Liu,et al.  The causal effect of mTORC1-dependent circulating protein levels on nonalcoholic fatty liver disease: A Mendelian randomization study. , 2023, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[16]  G. Sethi,et al.  PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer , 2023, Molecular Cancer.

[17]  Yao Yang,et al.  mTORC2 acts as a gatekeeper for mTORC1 deficiency-mediated impairments in ILC3 development , 2023, Acta Pharmacologica Sinica.

[18]  S. Taeb,et al.  The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in Cancer. , 2023, Cancer research.

[19]  P. Rangamani,et al.  Computational modeling of AMPK and mTOR crosstalk in glutamatergic synapse calcium signaling , 2023, bioRxiv.

[20]  D. Olive,et al.  Major pathways involved in macrophage polarization in cancer , 2022, Frontiers in Immunology.

[21]  R. Coppari,et al.  Hepatic non-parenchymal S100A9-TLR4-mTORC1 axis normalizes diabetic ketogenesis , 2022, Nature Communications.

[22]  Jing Gao,et al.  Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy , 2022, Frontiers in Immunology.

[23]  Aramati B. M. Reddy,et al.  High glutamine suppresses osteogenesis through mTORC1-mediated inhibition of the mTORC2/AKT-473/RUNX2 axis , 2022, Cell death discovery.

[24]  T. Sargeant,et al.  The mTOR–lysosome axis at the centre of ageing , 2021, FEBS open bio.

[25]  Yongshun Chen,et al.  Autophagy controls programmed death-ligand 1 expression on cancer cells (Review). , 2021, Biomedical reports.

[26]  Yongzhong Hou,et al.  Role of autophagy on cancer immune escape , 2021, Cell communication and signaling : CCS.

[27]  Oriol Vinyals,et al.  Highly accurate protein structure prediction with AlphaFold , 2021, Nature.

[28]  I. Park,et al.  Inhibition of mTORC1 through ATF4-induced REDD1 and Sestrin2 expression by Metformin , 2021, BMC cancer.

[29]  F. Schuit,et al.  Loss of Furin in β-Cells Induces an mTORC1-ATF4 Anabolic Pathway That Leads to β-Cell Dysfunction , 2020, Diabetes.

[30]  N. Cross,et al.  The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment , 2020, Frontiers in Immunology.

[31]  Jun Yu,et al.  Gut microbiome alters functions of mutant p53 to promote tumorigenesis , 2020, Signal Transduction and Targeted Therapy.

[32]  David C. Smith,et al.  Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer , 2020, British Journal of Cancer.

[33]  César Martín,et al.  Pathophysiology of Type 2 Diabetes Mellitus , 2020, International journal of molecular sciences.

[34]  M. Oren,et al.  The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic , 2020, Nature.

[35]  R. Cao,et al.  Phosphorylation of the mRNA cap-binding protein eIF4E and cancer. , 2020, Cellular signalling.

[36]  Sulaiman K. Marafie,et al.  Palmitic acid-induced lipotoxicity promotes a novel interplay between Akt-mTOR, IRS-1, and FFAR1 signaling in pancreatic β-cells , 2019, Biological Research.

[37]  S. Burgess,et al.  Impaired ketogenesis and increased acetyl-CoA oxidation promote hyperglycemia in human fatty liver. , 2019, JCI insight.

[38]  Jun Yu,et al.  Autophagy inhibition enhances PD-L1 expression in gastric cancer , 2019, Journal of Experimental & Clinical Cancer Research.

[39]  J. Loor,et al.  Methionine and valine activate the mammalian target of rapamycin complex 1 pathway through heterodimeric amino acid taste receptor (TAS1R1/TAS1R3) and intracellular Ca2+ in bovine mammary epithelial cells. , 2018, Journal of dairy science.

[40]  G. Shulman,et al.  Mechanisms of Insulin Action and Insulin Resistance. , 2018, Physiological reviews.

[41]  Mee-Sup Yoon The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling , 2017, Nutrients.

[42]  L. Zheng,et al.  Clk1‐regulated aerobic glycolysis is involved in glioma chemoresistance , 2017, Journal of neurochemistry.

[43]  D. Sabatini,et al.  mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.

[44]  T. Curiel,et al.  Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. , 2016, Cancer research.

[45]  Si Ming Man,et al.  NLRC3 is an inhibitory sensor of PI3K–mTOR pathways in cancer , 2016, Nature.

[46]  K Bhattacharya,et al.  PTEN negatively regulates mTORC2 formation and signaling in grade IV glioma via Rictor hyperphosphorylation at Thr1135 and direct the mode of action of an mTORC1/2 inhibitor , 2016, Oncogenesis.

[47]  J. Ting,et al.  Expression profile of innate immune receptors, NLRs and AIM2, in human colorectal cancer: correlation with cancer stages and inflammasome components , 2015, Oncotarget.

[48]  J. Sarkaria,et al.  A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. , 2015, Neuro-oncology.

[49]  T. Asano,et al.  A hepatic amino acid/mTOR/S6K-dependent signalling pathway modulates systemic lipid metabolism via neuronal signals , 2015, Nature Communications.

[50]  G. Thomas,et al.  A liaison between mTOR signaling, ribosome biogenesis and cancer. , 2015, Biochimica et biophysica acta.

[51]  G. Poulin,et al.  A nuclear role for the respiratory enzyme CLK-1/COQ7 in regulating mitochondrial stress responses and longevity , 2015, Nature Cell Biology.

[52]  Seamus J. Martin,et al.  Autophagy in malignant transformation and cancer progression , 2015, The EMBO journal.

[53]  D. Gu,et al.  Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma. , 2015, Cancer letters.

[54]  A. Dillin,et al.  Tipping the metabolic scales towards increased longevity in mammals , 2015, Nature Cell Biology.

[55]  Cheng Fang,et al.  Androgen Receptor, EGFR, and BRCA1 as Biomarkers in Triple-Negative Breast Cancer: A Meta-Analysis , 2015, BioMed research international.

[56]  N. Chandel Mitochondria as signaling organelles , 2014, BMC Biology.

[57]  R. Schneider,et al.  Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer. , 2014, Gynecologic oncology.

[58]  C. Rommel,et al.  PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.

[59]  O. Gavrilova,et al.  Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. , 2013, Cell reports.

[60]  L. Partridge,et al.  The Hallmarks of Aging , 2013, Cell.

[61]  C. Rommel,et al.  Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia , 2013, Leukemia.

[62]  P. Rabinovitch,et al.  mTOR is a key modulator of ageing and age-related disease , 2013, Nature.

[63]  N. Chandel,et al.  Physiological roles of mitochondrial reactive oxygen species. , 2012, Molecular cell.

[64]  I. Ray-Coquard,et al.  Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  Kira Glover-Cutter,et al.  TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. , 2012, Cell metabolism.

[66]  Dudley Lamming,et al.  Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity , 2012, Science.

[67]  P. Soares,et al.  The mTOR Signalling Pathway in Human Cancer , 2012, International journal of molecular sciences.

[68]  J. Sarkaria,et al.  North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. , 2011, International journal of radiation oncology, biology, physics.

[69]  C. Jung,et al.  ULK1 inhibits the kinase activity of mTORC1 and cell proliferation , 2011, Autophagy.

[70]  P. Houghton,et al.  Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin , 2011, Molecular Cancer Therapeutics.

[71]  K. Ryan,et al.  The multiple roles of autophagy in cancer , 2011, Carcinogenesis.

[72]  X. Zhao-Fan,et al.  mTOR partly mediates insulin resistance by phosphorylation of insulin receptor substrate-1 on serine(307) residues after burn. , 2011, Burns : journal of the International Society for Burn Injuries.

[73]  D. Sabatini,et al.  mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.

[74]  Philippe P Roux,et al.  mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide , 2010, The EMBO journal.

[75]  J. Sarkaria,et al.  Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks , 2010, Clinical Cancer Research.

[76]  Tohru Natsume,et al.  Tti1 and Tel2 Are Critical Factors in Mammalian Target of Rapamycin Complex Assembly* , 2010, The Journal of Biological Chemistry.

[77]  Chang Hwa Jung,et al.  mTOR regulation of autophagy , 2010, FEBS letters.

[78]  M. Kastan,et al.  The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. , 2010, Immunity.

[79]  Robert L Sutherland,et al.  PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality , 2010, International journal of cancer.

[80]  L. Partridge,et al.  Mechanisms of Life Span Extension by Rapamycin in the Fruit Fly Drosophila melanogaster , 2010, Cell metabolism.

[81]  Janet M. Thornton,et al.  Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span , 2009, Science.

[82]  M. Karsy,et al.  Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. , 2009, International journal of oncology.

[83]  M. Karsy,et al.  Inhibition of mTOR Activates the MAPK Pathway in Glioblastoma Multiforme. , 2009, Cancer genomics & proteomics.

[84]  J. Asara,et al.  Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1 , 2009, Molecular and Cellular Biology.

[85]  Marco Pahor,et al.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice , 2009, Nature.

[86]  A. Salminen,et al.  Regulation of the aging process by autophagy. , 2009, Trends in molecular medicine.

[87]  J. Blenis,et al.  Molecular mechanisms of mTOR-mediated translational control , 2009, Nature Reviews Molecular Cell Biology.

[88]  D. Sabatini,et al.  An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.

[89]  Robbie Loewith,et al.  Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 , 2009, PLoS biology.

[90]  D. Guertin,et al.  mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. , 2009, Cancer cell.

[91]  K. Alberti,et al.  Diagnosis and Classification of Diabetes Mellitus , 2009, Diabetes Care.

[92]  J. Ting,et al.  NLRs at the intersection of cell death and immunity , 2008, Nature Reviews Immunology.

[93]  S. Horvath,et al.  Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma , 2008, PLoS medicine.

[94]  D. Sabatini mTOR and cancer: insights into a complex relationship , 2006, Nature Reviews Cancer.

[95]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[96]  Matt Kaeberlein,et al.  Extension of chronological life span in yeast by decreased TOR pathway signaling. , 2006, Genes & development.

[97]  Alexandros Tzatsos,et al.  Nutrients Suppress Phosphatidylinositol 3-Kinase/Akt Signaling via Raptor-Dependent mTOR-Mediated Insulin Receptor Substrate 1 Phosphorylation , 2006, Molecular and Cellular Biology.

[98]  Matt Kaeberlein,et al.  Regulation of Yeast Replicative Life Span by TOR and Sch9 in Response to Nutrients , 2005, Science.

[99]  J. Blenis,et al.  Analysis of mTOR signaling by the small G‐proteins, Rheb and RhebL1 , 2005, FEBS letters.

[100]  Oliver E. Owen Ketone bodies as a fuel for the brain during starvation , 2005 .

[101]  R. Loewith,et al.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive , 2004, Nature Cell Biology.

[102]  Di Chen,et al.  The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span , 2004, Development.

[103]  T. Golub,et al.  mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.

[104]  S. Benzer,et al.  Regulation of Lifespan in Drosophila by Modulation of Genes in the TOR Signaling Pathway , 2004, Current Biology.

[105]  Tibor Vellai,et al.  Genetics: Influence of TOR kinase on lifespan in C. elegans , 2003, Nature.

[106]  Andrew G Fraser,et al.  Rates of Behavior and Aging Specified by Mitochondrial Function During Development , 2002, Science.

[107]  J. Crespo,et al.  Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. , 2002, Molecular cell.

[108]  D. Sabatini,et al.  mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery , 2002, Cell.

[109]  J. Avruch,et al.  Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action , 2002, Cell.

[110]  R. Burcelin,et al.  Hypoinsulinaemia, glucose intolerance and diminished β-cell size in S6K1-deficient mice , 2000, Nature.

[111]  A. Montag,et al.  Proinsulin processing by the subtilisin-related proprotein convertases furin, PC2, and PC3. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[112]  Jayson A. Neil,et al.  Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes. , 2015, Advances in biological regulation.

[113]  G. Schmitz,et al.  Metformin: An Inhibitor of mTORC1 Signaling , 2014 .

[114]  Y. Liu,et al.  Changes of plasma fibroblast growth factor-21 (FGF-21) in oral glucose tolerance test and effects of metformin on FGF-21 levels in type 2 diabetes mellitus. , 2013, Endokrynologia Polska.

[115]  N. Seidah The proprotein convertases, 20 years later. , 2011, Methods in molecular biology.